Perturbation of transforming growth factor (TGF)-β1 association with latent TGF-β binding protein yields inflammation and tumors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 48, 2008, Pages 18758-18763

  Yoshinaga, Keiji ^a,c   Obata, Hiroto ^a,d   Jurukovski, Vladimir ^a,e   Mazzieri, Roberta ^a,f   Chen, Yan ^a,g   Zilberberg, Lior ^a   Huso, David ^a,b   Melamed, Jonathan ^a   Prijatelj, Petra ^a,h   Todorovic, Vesna ^a   Dabovic, Branka ^a   Rifkin, Daniel B ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c KYUSHU UNIVERSITY   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e SUFFOLK COUNTY COMMUNITY COLLEGE   (United States)

^f SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^g MERCK RESEARCH LABORATORIES   (United States)

^h UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Tgf activation

Indexed keywords

CYSTEINE; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; SERINE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANUS TUMOR; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; INFLAMMATION; LANGERHANS CELL; LIFESPAN; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECTUM TUMOR; SIGNAL TRANSDUCTION; STOMACH TUMOR;

ANIMALS; CELLS, CULTURED; FIBROBLASTS; GASTRIC MUCOSA; INFLAMMATION; INTESTINAL MUCOSA; LANGERHANS CELLS; LATENT TGF-BETA BINDING PROTEINS; MICE; MICE, KNOCKOUT; NEOPLASMS; PROTEIN PRECURSORS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

ANIMALIA; MUS;

EID: 57749085683     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805411105     Document Type: Article

References (47)

1. Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGFbeta activation. J Cell Sci 116:217-224.
2. Derynck R, Miyazono K (2008) The TGF-â Family (Cold Spring Harbor Lab Press, Cold Spring Harbor, NY).
3. Saharinen J, Keski-Oja J (2000) Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell 11:2691-2704.
4. Rifkin DB (2005) Latent transforming growth factor-beta (TGF-beta) binding proteins: Orchestrators of TGF-beta availability. J Biol Chem 280:7409-7412.
5. Todorovic V, et al. (2005) Latent TGF-beta binding proteins. Int J Biochem Cell Biol 37:38-41.
6. Miyazono K, Olofsson A, Colosetti P, Heldin CH (1991) A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 10:1091-1101.
7. Dallas SL, et al. (2005) Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem 280:18871-18880.
8. Isogai Z, et al. (2003) Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 278:2750-2757.
9. Mazzieri R, et al. (2005) Expression of truncated latent TGF-beta-binding protein modulates TGF-beta signaling. J Cell Sci 118:2177-2187.
10. Neptune ER, et al. (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33:407-411.
11. Munger JS, et al. (1998) The integrin αvβ6 binds and activates latent TGF1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319-328.
12. Annes JP, Chen Y, Munger JS, Rifkin DB (2004) Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol 165:723-734.
13. Fontana L, et al. (2005) Fibronectin is required for integrin alphavbeta6-mediated activation of latent TGF-beta complexes containing LTBP-1. FASEB J 19:1798-1808.
14. Wipff PJ, Rifkin DB, Meister JJ, Hinz B (2007) Myofibroblast contraction activates latent TGF- 1 from the extracellular matrix. J Cell Biol 179:1311-1323.
15. Jenkins RG, et al. (2006) Ligation of protease-activated receptor 1 enhances alpha (v) beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 116: 1606-1614.
16. Dabovic B, et al. (2002) Bone abnormalities in latent TGF-β binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-β bioavailability. J Cell Biol 156:227-232.
17. Dabovic B, et al. (2002) Bone defects in latent TGF-beta binding protein (Ltbp)-3 null mice; a role for Ltbp in TGF-beta presentation. J Endocrinol 175:129-141.
18. Sterner-Kock A, et al. (2002) Disruption of the gene encoding the latent transforming growth factor-beta binding protein 4 (LTBP-4) causes abnormal lung development, cardiomyopathy, and colorectal cancer. Genes Dev 16:2264-2273.
19. Todorovic V, et al. (2007) Long form of latent TGF-{beta} binding protein 1 (Ltbp1L) is essential for cardiac outflow tract septation and remodeling. Development 134:3723-3732.
20. Choudhary B, et al. (2006) Cardiovascular malformations with normal smooth muscle differentiation in neural crest-specific type II TGFbeta receptor (Tgfbr2) mutant mice. Dev Biol 289:420-429.
21. Erlebacher A, Derynck R (1996) Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 132:195-210.
22. Markowitz S, et al. (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338.
23. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S (1997) Frequency of Smad gene mutations in human cancers. Cancer Res 57:2578-2580.
24. Kallapur S, Ormsby I, Doetschman T (1999) Strain dependency of TGFbeta1 function during embryogenesis. Mol Reprod Dev 52:341-349.
25. Nakajima H, et al. (2000) Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res 86:571-579.
26. Peterson SR, Gadbois DM, Bradbury EM, KraemerPM(1995) Immortalization of human fibroblasts by SV40 large T antigen results in the reduction of cyclin D1 expression and subunit association with proliferating cell nuclear antigen and Waf1. Cancer Res 55:4651-4657.
27. Borkowski TA, Letterio JJ, Farr AG, Udey MC (1996) A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: The skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J Exp Med 184:2417-2422.
28. Thomas RM, et al. (2001) Appearance of Langerhans cells in the epidermis of Tgfb1(-/-) SCID mice: Paracrine and autocrine effects of transforming growth factor-beta 1 and -beta 2(1). J Invest Dermatol 117:1574-1580.
29. Kulkarni AB, et al. (1993) Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770-774.
30. Shull MM, et al. (1992) Targeted disruption of the mouse transforming growth factor-β1 gene results in mulitfocal inflammatory disease. Nature 359:693-699.
31. de Visser KE, KastWM(1999) Effects of TGF-beta on the immune system: Implications for cancer immunotherapy. Leukemia 13:1188-1199.
32. Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20.
33. Warner BJ, Blain SW, Seoane J, Massague J (1999) Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. Mol Cell Biol 19:5913-5922.
34. Chen Y, et al. (2005) Amino acid requirements for formation of the TGF-beta-latent TGF-beta binding protein complexes. J Mol Biol 345:175-186.
35. Ahamed J, et al. (2008) In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-{beta}1 (TGF-{beta}1). Blood 112:3650-3660.
36. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich E (1994) Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J Biol Chem 269:26775-26782.
37. Mu D, et al. (2002) The integrin alpha (v) beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 157:493-507.
38. Engle SJ, et al. (1999) Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59:3379-3386.
39. Yang Z, et al. (2007) Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol 176:787-793.
40. Takaku K, et al. (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92:645-656.
41. Zhu Y, Richardson JA, Parada LF, Graff JM (1998) Smad3 mutant mice develop metastatic colorectal cancer. Cell 94:703-714.
42. Eppert K, et al. (1996) MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543-552.
43. Grady WM, et al. (1999) Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 59:320-324.
44. Hahn SA, et al. (1996) DPC4, a candidate tumor suppressor gene athumanchromosome 18q21.1. Science 271:350-353.
45. Bhowmick NA, et al. (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848-851.
46. Kim BG, et al. (2006) Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441:1015-1019.
47. Wang Y, Zhu W, Levy DE (2006) Nuclear and cytoplasmic mRNA quantification by SYBR green based real-time RT-PCR. Methods 39:356-362.